[go: up one dir, main page]

AU2003259965A1 - Methods and compositions for modulating amyloid beta - Google Patents

Methods and compositions for modulating amyloid beta

Info

Publication number
AU2003259965A1
AU2003259965A1 AU2003259965A AU2003259965A AU2003259965A1 AU 2003259965 A1 AU2003259965 A1 AU 2003259965A1 AU 2003259965 A AU2003259965 A AU 2003259965A AU 2003259965 A AU2003259965 A AU 2003259965A AU 2003259965 A1 AU2003259965 A1 AU 2003259965A1
Authority
AU
Australia
Prior art keywords
compositions
methods
amyloid beta
modulating amyloid
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259965A
Other versions
AU2003259965A8 (en
Inventor
Maria Kounnas
Aaron Patrick
Gonul Velicelebi
Steven Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TorreyPines Therapeutics Inc
Original Assignee
TorreyPines Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TorreyPines Therapeutics Inc filed Critical TorreyPines Therapeutics Inc
Publication of AU2003259965A1 publication Critical patent/AU2003259965A1/en
Publication of AU2003259965A8 publication Critical patent/AU2003259965A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003259965A 2002-08-20 2003-08-20 Methods and compositions for modulating amyloid beta Abandoned AU2003259965A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40541702P 2002-08-20 2002-08-20
US60/405,417 2002-08-20
US41197402P 2002-09-18 2002-09-18
US60/411,974 2002-09-18
PCT/US2003/026173 WO2004018997A2 (en) 2002-08-20 2003-08-20 Methods and compositions for modulating amyloid beta

Publications (2)

Publication Number Publication Date
AU2003259965A1 true AU2003259965A1 (en) 2004-03-11
AU2003259965A8 AU2003259965A8 (en) 2004-03-11

Family

ID=31949893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259965A Abandoned AU2003259965A1 (en) 2002-08-20 2003-08-20 Methods and compositions for modulating amyloid beta

Country Status (2)

Country Link
AU (1) AU2003259965A1 (en)
WO (1) WO2004018997A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1563066A4 (en) * 2002-11-04 2006-06-07 Bioarctic Neuroscience Ab Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
EP1563067A4 (en) * 2002-11-04 2006-06-07 Icogenex Corp Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
CA2525547C (en) 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
CA2604057C (en) 2005-04-06 2014-02-11 Randall John Bateman Methods for measuring the metabolism of neurally derived biomolecules in vivo
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
CN117903302A (en) 2005-11-30 2024-04-19 Abbvie 公司 Anti-aβ globulomer antibodies, related products thereof, methods of producing said antibodies, uses of said antibodies, and methods of use
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
NZ585528A (en) 2007-11-21 2012-08-31 Pharmaxis Ltd Haloallylamine inhibitors of ssao/vap-1 and uses therefor
CA2725326A1 (en) * 2008-05-23 2009-11-26 University Of Rochester Compositions and methods relating to detection of soluble e-cadherin in neurodegenerative disease
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
JP6069661B2 (en) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Compositions and uses thereof in the regulation of various amyloid beta peptide alloform levels
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
SG10201707020TA (en) 2012-05-02 2017-10-30 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
EP3200832B1 (en) 2014-09-30 2020-07-29 Washington University Tau kinetic measurements
JP6672296B2 (en) 2014-10-31 2020-03-25 ザ ジェネラル ホスピタル コーポレイション Powerful gamma-secretase modulator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies

Also Published As

Publication number Publication date
AU2003259965A8 (en) 2004-03-11
WO2004018997A3 (en) 2005-06-23
WO2004018997A2 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
AU2003259965A1 (en) Methods and compositions for modulating amyloid beta
EP1578940A3 (en) Methods and compositions for diagnosing dysplasia
AU2003241478A1 (en) Nanoparticulate sterol formulations and sterol combinations
WO2003073826A8 (en) Novel compositions and methods for cancer
AU2003266058A1 (en) Antimicrobial composition and method for use
AU2003267644A1 (en) Dental compositions and methods
AU2003226094A1 (en) Compounds and methods
AU2003234794A1 (en) Composition and method for temporarily fixing solid
AU2003256805A1 (en) Compounds compositions and methods
AU2003287443A1 (en) Compositions and methods for pain reduction
AU2002950744A0 (en) Composition
AU2003211453A1 (en) External compositions for the skin
AU2003266815A1 (en) Immunoglobulin compositions and methods
AU2003236353A1 (en) Photopolymerizable composition
AU2003225104A1 (en) Composition for reducing malodors and method for using the same
WO2003072064A9 (en) Methods and compositions for regulating adipogenesis
AU2003276129A1 (en) Compositions and methods for darkening the skin
AU2003208411A1 (en) Anti-glycolytic composition
AU2002950831A0 (en) Rheometer
AU2003269904A1 (en) Antigen-polymer compositions
EP1576109A3 (en) Methods and compositions for categorizing patients
AU2003221050A1 (en) Remedy for hypermyotonia
AU2003222058A1 (en) Materials and methods for inhibiting wip-1
AU2003275476A1 (en) Cast collimator and method for making same
AU2003295574A1 (en) Method and compositions for temporarily incapaciting subjets

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase